Skip to content
Review Open access

Hannibal ante portas: B7-H3-directed therapies at the gates of precision oncology.

Nov 2026 · Biomolecules & biomedicine · 0 citations · 20 references
Medicine

Abstract

Precision oncology has revolutionized cancer treatment, improving outcomes and extending survival even in aggressive cancers like small-cell lung cancer. Molecularly targeted therapies and immune checkpoint inhibitors (e.g., PD-1/PD-L1) are now standard. Recently, the immune checkpoint regulator B7-H3 (CD276) has emerged as a promising therapeutic target, especially for novel antibody-drug conjugates (ADCs). This article highlights recent advances in B7-H3-targeted ADCs, emphasizing the urgent need for reliable predictive biomarkers to guide patient selection and optimize treatment.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.